Ezequiel Ruiz-Mateos

List of Publications by Year
in descending order

122	3,056	172457	206112
papers	citations	29 h-index	48 g-index

127	127	127	4214
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. Journal of Infectious Diseases, 2022, 225, 1040-1049.	4.0	13
2	Past and future of HIV infection. A document based on expert opinion. Revista Espanola De Quimioterapia, 2022, 35, 131-156.	1.3	2
3	SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression. Microorganisms, 2022, 10, 143.	3.6	11
4	Fetuinâ€A, interâ€Î±â€trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. Clinical and Translational Medicine, 2022, 12, e704.	4.0	11
5	Immunoescape of HIV-1 in Env-EL9 CD8â€‰+â€‰T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control. Retrovirology, 2022, 19, 6.	2.0	3
6	Deciphering the quality of SARSâ€CoVâ€2 specific Tâ€cell response associated with disease severity, immune memory and heterologous response. Clinical and Translational Medicine, 2022, 12, e802.	4.0	8
7	Elevated Î±-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control. Frontiers in Immunology, 2022, 13, 822272.	4.8	4
8	Mesenchymal stromal cells in human immunodeficiency virusâ€infected patients with discordant immune response: Early results of a phase I/II clinical trial. Stem Cells Translational Medicine, 2021, 10, 534-541.	3.3	8
9	The Other Side of SARS-CoV-2 Infection: Neurological Sequelae in Patients. Frontiers in Aging Neuroscience, 2021, 13, 632673.	3.4	7
10	Differential miRNA plasma profiles associated with the spontaneous loss of HIVâ€1 control: miRâ€199aâ€3p and its potential role as a biomarker for quick screening of elite controllers. Clinical and Translational Medicine, 2021, 11, e474.	4.0	3
11	Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cellular and Molecular Immunology, 2021, 18, 2128-2139.	10.5	81
12	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. Frontiers in Immunology, 2021, 12, 730691.	4.8	2
13	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1Î², Early Predictors of Severe COVID-19. Microorganisms, 2021, 9, 2259.	3.6	14
14	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Science Translational Medicine, 2021, 13, eabl4097.	12.4	52
15	Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?. Journal of Antimicrobial Chemotherapy, 2020, 75, 200-207.	3.0	4
16	CD300a identifies a CD4+ memory T cell subset with a higher susceptibility to HIV-1 infection. Aids, 2020, 34, 1249-1252.	2.2	2
17	Persistent HIVâ€controllers are more prone to spontaneously clear HCV: a retrospective cohort study. Journal of the International AIDS Society, 2020, 23, e25607.	3.0	2
18	Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3

#	Article	IF	Citations
19	Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Scientific Reports, 2020, 10, 1902.	3.3	50
20	Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway. Nature Communications, 2020, 11, 821.	12.8	25
21	Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a. Scientific Reports, 2020, 10, 6070.	3.3	4
22	PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients. Journal of Clinical Investigation, 2020, 130, 2872-2887.	8.2	24
23	Antiretroviral Treatment for HIV Elite Controllers?. Pathogens and Immunity, 2020, 5, 121.	3.1	11
24	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. Scientific Reports, 2019, 9, 15722.	3.3	4
25	Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects. Antiviral Research, 2019, 169, 104527.	4.1	4
26	Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection. EBioMedicine, 2019, 42, 86-96.	6.1	55
27	High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use. Virus Research, 2019, 264, 40-44.	2.2	6
28	Development of Immature CD4+CD8+T Cells Into Mature CD4+ T Cells Requires Alpha-1 Antitrypsin as Observed by Treatment in HIV-1 Infected and Uninfected Controls. Frontiers in Cell and Developmental Biology, 2019, 7, 278.	3.7	6
29	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. Journal of Infectious Diseases, 2019, 219, 867-876.	4.0	23
30	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects. , 2019, , 1865-1882.		0
31	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. Atherosclerosis, 2018, 273, 28-36.	0.8	15
32	Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure. EBioMedicine, 2018, 28, 15-16.	6.1	5
33	Pegylated Interferon-Î±â€“Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapyâ€“Treated HIV-1/Hepatitis C Virusâ€“Coinfected Patients. Clinical Infectious Diseases, 2018, 66, 1910-1917.	5.8	30
34	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Medicine, 2018, 16, 30.	5.5	19
35	Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients. Aids, 2018, 32, 1035-1041.	2.2	3
36	Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	4

#	Article	IF	Citations
37	Association of heterozygous CCR5Î”32 deletion with survival in HIV-infection: A cohort study. Antiviral Research, 2018, 150, 15-19.	4.1	6
38	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	3.4	58
39	Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearanceâ€”Supercontrollers. Frontiers in Immunology, 2018, 9, 2897.	4.8	15
40	Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients. International Journal of Medical Sciences, 2018, 15, 95-100.	2.5	2
41	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects. , 2018, , 1-18.		0
42	Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells. Journal of Virology, 2018, 92, .	3.4	16
43	Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination. Journal of Translational Medicine, 2018, 16, 238.	4.4	5
44	Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers. Frontiers in Immunology, 2018, 9, 1709.	4.8	11
45	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833.	5.8	28
46	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, .	12.4	135
47	A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
48	Relationship between CCR5(WT/Î”32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. Clinical Microbiology and Infection, 2017, 23, 318-324.	6.0	5
49	Reply to Kuniholm et al. Clinical Infectious Diseases, 2017, 65, 1244-1245.	5.8	0
50	Thymic Function Impacts the Peripheral CD4/CD8 Ratio of HIV-Infected Subjects. Clinical Infectious Diseases, 2017, 64, 152-158.	5.8	26
51	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. Clinical Infectious Diseases, 2017, 64, 1191-1197.	5.8	30
52	CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. Thrombosis and Haemostasis, 2017, 117, 1141-1149.	3.4	9
53	Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens. Journal of Translational Medicine, 2017, 15, 259.	4.4	6
54	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	2.5	30

#	Article	IF	Citations
55	Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients. Drug Design, Development and Therapy, 2016, 10, 353.	4.3	2
56	Rate and predictors of progression in elite and viremic HIV-1 controllers. Aids, 2016, 30, 1209-1220.	2.2	69
57	Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients. Viral Immunology, 2016, 29, 471-477.	1.3	7
58	Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 6398-6401.	3.2	0
59	Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects. Clinical Microbiology and Infection, 2016, 22, 461.e1-461.e5.	6.0	10
60	Monocyte Phenotype and Polyfunctionality Are Associated With Elevated Soluble Inflammatory Markers, Cytomegalovirus Infection, and Functional and Cognitive Decline in Elderly Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 610-618.	3.6	33
61	Analysis of Non-AIDS-Defining Events in HIV Controllers. Clinical Infectious Diseases, 2016, 62, 1304-1309.	5.8	34
62	Phenotype and Polyfunctional Deregulation Involving Interleukin 6 (IL-6)â€“ and IL-10â€“Producing Monocytes in HIV-Infected Patients Receiving Combination Antiretroviral Therapy Differ From Those in Healthy Older Individuals. Journal of Infectious Diseases, 2016, 213, 999-1007.	4.0	14
63	WNT Signaling Suppression in the Senescent Human Thymus. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 273-281.	3.6	23
64	IFNÎ³^{â^'}TNFÎ±^{â^'}IL2^{â^'}MIP1Î±^{â^'}CD107a⁺PRF1⁺CD8 pp65-Specific T-Cell Response Is Independently Associated With Time to Death in Elderly Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 1210-1218.	3.6	11
65	Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naÃ¯ve HIV-infected patients. Antiviral Research, 2015, 121, 94-96.	4.1	5
66	IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. Clinical Microbiology and Infection, 2015, 21, 289.e1-289.e4.	6.0	18
67	Hepatitis C Therapy With Interferon-Î± and Ribavirin Reduces CD4 T-Cellâ€“Associated HIV-1 DNA in HIV-1/Hepatitis C Virusâ€“Coinfected Patients. Journal of Infectious Diseases, 2014, 209, 1315-1320.	4.0	60
68	TNF-Â levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. Journal of Antimicrobial Chemotherapy, 2014, 69, 3041-3046.	3.0	46
69	Efficacy and tolerability after 24weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIVâ€“HCV coinfected subjects. Antiviral Research, 2014, 104, 59-61.	4.1	6
70	Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects. Journal of Infectious Diseases, 2014, 210, 890-898.	4.0	23
71	Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism. Antimicrobial Agents and Chemotherapy, 2014, 58, 2167-2185.	3.2	61
72	Maintenance of virologic efficacy and decrease in levels of Î²2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy. Antiviral Research, 2014, 111, 26-32.	4.1	14

#	Article	IF	Citations
73	Thymic function failure and C-reactive protein levels are independent predictors of all-cause mortality in healthy elderly humans. Age, 2013, 35, 251-259.	3.0	95
74	IL28B Single-Nucleotide Polymorphism rs12979860 Is Associated With Spontaneous HIV Control in White Subjects. Journal of Infectious Diseases, 2013, 207, 651-655.	4.0	22
75	Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects. Clinical Microbiology and Infection, 2013, 19, 558-565.	6.0	23
76	Prevalence of HIV-1 Dual Infection in Long-Term Nonprogressorâ€“Elite Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 225-231.	2.1	8
77	Long-Term Suppressive Combined Antiretroviral Treatment Does Not Normalize the Serum Level of Soluble CD14. Journal of Infectious Diseases, 2013, 207, 1221-1225.	4.0	69
78	Differential Gag-Specific Polyfunctional T Cell Maturation Patterns in HIV-1 Elite Controllers. Journal of Virology, 2012, 86, 3667-3674.	3.4	52
79	Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers. Journal of Virology, 2012, 86, 4245-4252.	3.4	66
80	Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. Journal of Antimicrobial Chemotherapy, 2012, 67, 1228-1237.	3.0	29
81	Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods. Antimicrobial Agents and Chemotherapy, 2012, 56, 1202-1207.	3.2	19
82	HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2012, 56, 3981-3983.	3.2	7
83	Plasmacytoid Dendritic Cells (pDCs) From HIV Controllers Produce Interferon-Î± and Differentiate Into Functional Killer pDCs Under HIV Activation. Journal of Infectious Diseases, 2012, 206, 790-801.	4.0	62
84	Detectable Viral Load Aggravates Immunosenescence Features of CD8 T-Cell Subsets in Vertically HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 447-454.	2.1	20
85	CD4 T-cell regeneration in HIV-1 elite controllers. Aids, 2012, 26, 701-706.	2.2	28
86	Prevalence of Transmitted HIV-1 Drug Resistance Mutations in Children and Adolescents in SÃ£o Paulo, Brazil. Pediatric Infectious Disease Journal, 2012, 31, e255-e257.	2.0	21
87	Different biological significance of sCD14 and LPS in HIV-infection: Importance of the immunovirology stage and association with HIV-disease progression markers. Journal of Infection, 2012, 65, 431-438.	3.3	41
88	Effect of Maraviroc on HIV Disease Progression-Related Biomarkers. Antimicrobial Agents and Chemotherapy, 2012, 56, 5858-5864.	3.2	19
89	Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. Antiviral Research, 2012, 95, 207-211.	4.1	6
90	T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. Journal of Infection, 2012, 64, 417-423.	3.3	9

#	Article	IF	Citations
91	Simplified sequence-specific oligonucleotide-based polymerase chain reaction protocol to characterize human major histocompatibility complex A*02 and A*24 specificities. Human Immunology, 2011, 72, 869-871.	2.4	4
92	Hepatitis C virus replication in Caucasian HIV controllers. Journal of Viral Hepatitis, 2011, 18, e350-7.	2.0	29
93	Discordance rates between TrofileÂ® test and short-term virological response to maraviroc. Antiviral Research, 2011, 89, 182-185.	4.1	10
94	Age-related deregulation of naive T cell homeostasis in elderly humans. Age, 2011, 33, 197-207.	3.0	89
95	HIV Infection-Related Premature Immunosenescence: High Rates of Immune Exhaustion After Short Time of Infection. Current HIV Research, 2011, 9, 289-294.	0.5	33
96	Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors. Antimicrobial Agents and Chemotherapy, 2011, 55, 4664-4669.	3.2	11
97	Long-Term Immunovirogical Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice. Current HIV Research, 2010, 8, 482-486.	0.5	17
98	CD27 and CCR7 expression on naive T cells, are both necessary?. Immunology Letters, 2010, 127, 157-158.	2.5	19
99	A reliable and simplified sj/Î²-TREC ratio quantification method for human thymic output measurement. Journal of Immunological Methods, 2010, 352, 111-117.	1.4	54
100	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. Journal of Antimicrobial Chemotherapy, 2010, 65, 2493-2501.	3.0	35
101	TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches. Journal of Clinical Microbiology, 2010, 48, 4453-4458.	3.9	21
102	High Levels of CD57+CD28- T-Cells, Low T-Cell Proliferation and Preferential Expansion of Terminally Differentiated CD4+ T-Cells in HIVElite Controllers. Current HIV Research, 2010, 8, 471-481.	0.5	15
103	Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 64, 845-849.	3.0	28
104	Inositol pyrophosphate mediated pyrophosphorylation of AP3B1 regulates HIV-1 Gag release. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21161-21166.	7.1	127
105	CD63 Is Not Required for Production of Infectious Human Immunodeficiency Virus Type 1 in Human Macrophages. Journal of Virology, 2008, 82, 4751-4761.	3.4	46
106	In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. Journal of Cell Biology, 2007, 177, 329-341.	5.2	292
107	In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. Journal of Experimental Medicine, 2007, 204, i13-i13.	8.5	0
108	Disseminate and fatal cytomegalovirus disease with thymitis in a naive HIV-patient after early initiation of HAART: Immune restoration disease?. Journal of Clinical Virology, 2006, 36, 13-16.	3.1	5

#	Article	IF	Citations
109	Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infectious Diseases, 2006, 6, 112.	2.9	29
110	Thymic Function-Related Markers Within the Thymus and Peripheral Blood: Are They Comparable?. Journal of Clinical Immunology, 2006, 26, 96-100.	3.8	16
111	Immunovirologic Characteristics of Human Immunodeficiency Virus-Infected Patients Consisting Mainly of Injecting Drug Users on Highly Active Antiretroviral Treatment with Prolonged Virologic Failure. Viral Immunology, 2006, 19, 759-767.	1.3	9
112	Effect of Hepatitis C Virus Coinfection on Humoral Immune Alterations in NaÃ¯ve HIV-Infected Adults on HAART: A Three Year Follow-Up Study. Journal of Clinical Immunology, 2005, 25, 296-302.	3.8	10
113	High Thymic Volume Is Associated With Viral Replication and Immunologic Impairment Only Early After HAART Interruption in Chronic HIV Infection. Viral Immunology, 2005, 18, 740-746.	1.3	11
114	Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART)1. Clinical and Experimental Immunology, 2004, 136, 501-506.	2.6	41
115	Immunity in HIV-1-Infected Adults with a Previous State of Moderate-Severe Immune-Suppression and More Than 500 CD4+ T Cell After Highly Active Antiretroviral Therapy. Journal of Clinical Immunology, 2004, 24, 379-388.	3.8	16
116	Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2003, 53, 95-101.	3.0	21
117	Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy. Aids, 2003, 17, 947-954.	2.2	36
118	Comparison of thymic function-related markers to predict early CD4 T-cell repopulation in adult HIV-infected patients on HAART. Antiviral Therapy, 2003, 8, 289-94.	1.0	5
119	Comparison of Thymic Function-Related Markers to Predict Early Cd4 T-Cell Repopulation in Adult HIV-Infected Patients on Haart. Antiviral Therapy, 2003, 8, 289-294.	1.0	13
120	Evidence of Thymic Function in Heavily Antiretroviralâ€Treated Human Immunodeficiency Virus Type 1â€“Infected Adults with Longâ€Term Virologic Treatment Failure. Journal of Infectious Diseases, 2002, 186, 410-414.	4.0	22
121	Changes in thymus volume in adult HIV-infected patients under HAART: correlation with the T-cell repopulation. Clinical and Experimental Immunology, 2002, 130, 121-126.	2.6	24
122	Baseline Thymic Volume is a Predictor for CD4 T Cell Repopulation in Adult HIV-Infected Patients under Highly Active Antiretroviral Therapy. Antiviral Therapy, 2002, 7, 159-163.	1.0	17